Key points are not available for this paper at this time.
Regenerative medicine aims at changing modern medicine practice by eliminating core reasons of diseases and disorders. Regenerative medicine includes gene therapy, cell therapy and products of tissue engineering that are destined for augmentation, regeneration or replacement of organs, tissues, genes and metabolic processes in the organism. Biomaterials are amongst key components of regenerative medicine on which successful strategies are based. The review of biotechnological methods implemented in the USP and DSP stages with the use of B. mori was made. The methods analysed are aimed at improving quality characteristics and obtaining new kinds of biomaterials to meet the needs of regenerative medicine and biomedicine. The diversity of biotechnological solutions that allow to gain a wide spectrum of biomaterials (incl. derivatives of cocoon shell such as fibroin, sericin and their composites; recombinant derivatives; antimicrobial peptides; modified transgenic silk fibres;transgenic fibres that contain growth factors and peptides; etc.) is a unique basis for the bioindustrial platform on the B. mori basis.
Yumatov et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: